Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

SECRETED FACTORS IN CARDIAC REMODELING PROVOKE TUMORIGENESIS AND END ORGAN DAMAGE IN HEART FAILURE

Project description

Secreted factors in the aetiology of heart failure-associated multimorbidity

Heart failure (HF) treatment has improved over the years, yet morbidity and mortality remain high. The current HF treatment is heart-oriented, in part neglecting the systemic effects associated with morbidity and mortality. The EU-funded SECRETE-HF project will study the role of secreted factors in the aetiology of HF-associated multimorbidity. The focus will be on the susceptibility of HF patients for incident cancer, next to co-morbid conditions such as renal, liver and pulmonary disease. The research will involve cell and mouse models of colon and renal tumours, studying several aetiologies of HF. In these models, the cardiac secretome will be mapped in great detail. The study will identify overlapping and diverse factors from different HF forms involved in the tumour formation and organ dysfunction.

Objective

The objective of SECRETE-HF is to demonstrate the effects of secreted factors from failing hearts to explain the etiology of multimorbidity in heart failure (HF). The project focuses on two co-morbid patterns: 1) the emerging susceptibility of HF patients for incident cancer, 2) the more established co-morbid conditions of renal, liver and pulmonary disease in HF. The rationale is:
• HF treatment has improved, yet morbidity and mortality remain high, which can be attributed to co-morbid conditions rather than pump failure alone.
• HF treatment is heart-oriented, neglecting the systemic effects that come with HF, and the associated morbidity and mortality.
• Using innovative experimental approaches such as organ transplant models, target finding, and deep phenotyping of clinical databases I will dissect HF-derived effects on tumor growth and organ damage.
OBJECTIVES
1. To establish the effects of HF, due to different etiologies, using the state-of-the-art heart transplantation murine model with (spontaneous) formation of colon and renal tumors, and phenotype tumor growth, as well as the main HF-affected organs: kidney, liver and lungs.
2. Identification of the cardiac secretome using unbiased approaches.
3. Integrate the results and identify overlapping and diverse factors from different HF forms, and their consequences for tumor growth and kidney/liver/lung remodeling.
4. Validate discoveries in human cohorts with data on incident HF, cancer and organ function.
5. Create clinical algorithms to detect, monitor and act on extra-cardiac disease.
WORKPACKAGES
WP 1: Create HF, murine heart transplantation models; phenotype tumor growth and organ involvement.
WP 2: Explore the proteomic, metabolomic and extracellular vesicle profiles from HF subforms.
WP 3: Validate secreted factors in vitro and in vivo.
WP 4: Validate human relevance in large population-based cohorts with unique phenotyping.
WP 5: Describe added value of novel markers and design clinical

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

ERC-COG - Consolidator Grant

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) ERC-2018-COG

See all projects funded under this call

Host institution

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 432 748,06
Address
DR MOLEWATERPLEIN 40
3015 GD Rotterdam
Netherlands

See on map

Activity type
Higher or Secondary Education Establishments
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 432 748,06

Beneficiaries (2)

My booklet 0 0